Recursion Acquires Vium Strengthening Its Attempts to Industrialize Drug Discovery

Recursion, Vium | July 29, 2020

Recursion, a digital biology company leading in the industrialization of drug discovery, today announced its acquisition of Vium, a digital vivarium company. Vium’s platform combines computer vision, machine learning and sensor technologies to non-invasively collect and derive insights from digital biomarkers in preclinical in vivo research. Recursion’s acquisition of Vium signals continued and rapid integration of advanced technologies to grow its drug discovery pipeline of over 30 programs along with programs developed jointly with large pharmaceutical partners.

“Technology is set to change the pace, scale and cost of drug discovery over the coming decades. At Recursion, we are building a vast machine to rapidly discover drugs through the integration of technology at every step in the process,” said Chris Gibson, Ph.D., co-founder and CEO of Recursion. “Bringing the fantastic team at Vium in-house will enable us to build on our core technology and vision, augmenting our huge in vitro datasets with large, complementary in vivo datasets, and advancing our mission to decode biology to radically improve patient lives.”

Spotlight

To finish off our marketing excellence focus month, we speak with David Richardson from Cutting Edge Information about the importance for pharma to have a successful marketing strategy.

Spotlight

To finish off our marketing excellence focus month, we speak with David Richardson from Cutting Edge Information about the importance for pharma to have a successful marketing strategy.

Related News

BUSINESS INSIGHTS

Hikma and FAES Farma enter into exclusive licensing agreement for the commercialisation of Bilastine tablets in the US

Hikma Pharmaceuticals PLC | September 21, 2021

Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, announces the signing of an exclusive US license agreement with FAES Farma S.A. to commercialise Bilastine tablets, a non-sedating second generation antihistamine molecule for the treatment of allergic rhinitis and urticaria. Under the terms of the agreement, Hikma will be responsible for obtaining regulatory approval of Bilastine by the US Food and Drug Administration (FDA) and for the commercialisation of the product in the US following approval. Hikma will provide FAES with an upfront payment, regulatory approval and commercial milestone payments as well as royalties. The agreement builds upon Hikma and FAES Farma's existing partnership on Bilastine in the Middle East and North Africa, where Hikma is the exclusive licensee for Bilastine in 15 countries. We are pleased to form this partnership with FAES Farma for Bilastine, which builds on our growing position in the allergy market and further advances our objective of strengthening our specialty business in the US. Since its first launch in Europe in 2011, Bilastine has been successfully commercialised as a leading allergy brand in more than 100 countries. By introducing Bilastine in the US, Hikma is further solidifying its presence in the allergy market, and we will leverage our existing salesforce promoting our specialty portfolio, including our partnership with Eyevance Pharmaceuticals for the co-promotion of ZERVIATE® and our forthcoming branded seasonal allergic rhinitis nasal spray Ryaltris™. We look forward to bringing this new treatment option to US patients. - Brian Hoffmann, President of Hikma Generics. About Bilastine Bilastine is a non-sedating second generation antihistamine molecule for the treatment of allergic rhinitis and urticaria. Bilastine is currently approved in more than 120 countries and achieved more than €290 million in worldwide sales in 2020. If approved by the FDA, Bilastine would be the first New Chemical Entity antihistamine approved in the US since 2007. About Hikma Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world.

Read More

PHARMACY MARKET

Kairos Pharma Received FDA Approval of the IND Application for an Investigational New Drug

Kairos Pharma, Ltd. | March 15, 2022

Kairos Pharma, Ltd. a privately-held clinical-stage biotechnology company focused on cancer drug resistance and immunotherapy, announced today that its activated T cell therapy, KROS 201, has received FDA approval to move forward with a Phase 1 clinical trial in patients with recurrent glioblastoma. Kairos Pharma is funding the phase I trial, which will occur at Cedars Sinai Medical Center in Los Angeles. John Yu, M.D., Kairos CEO, commented, "This IND acceptance is the second substantial clinical milestone within the past month as Kairos accelerates toward its clinical goals for 2022. This first-in-man Phase 1 clinical trial will activate T cells against the cancer stem cells at the root of glioblastoma." "This achievement pushes the envelope of immune therapies designed to target T cells against devastating cancers." Neil Bhowmick, Ph.D., Kairos Chief Scientific Officer KROS 201 activated T cells (ATCs) are killer T cells created in cell culture by activating a patient's white blood cells with cytokines or T cell activating signals and priming dendritic cells with antigens specific to glioblastoma cancer stem cells. Patients with recurrent glioblastoma are given the strongly activated T cells intravenously. As a result, cancer stem cells, which are the source of cancer, are killed by these cells. In February, the FDA granted an IND for a Phase 2 trial of ENV105 with apalutamide, in addition to the planned Phase 1 trial of activated T cell treatment for KROS 201. In 2022, an ENV105 Phase 1 trial with Tagrisso (AstraZeneca) for lung cancer is expected. Kairos Pharma also published a notice of allowance of their patent Compositions and Methods for Treating Fibrosis by the United States Patent and Trademark Office, which coincides with the advancement of its clinical milestones. The method of treating fibrosis and certain types of cancer, the composition of matter, and the administration of therapy utilizing KROS-401, a cyclic peptide inhibitor of the IL-4 and IL-13 cytokine receptor complex, are all covered by this patent. This drug has been proven to treat fibrosis and cancer by reversing the M1 to M2 immunosuppressive macrophage shift in cancer and fibrosis. CEO of Kairos Pharma, Dr. John Yu, stated, "This milestone further supports the already substantial and diversified intellectual property portfolio of Kairos and enables the unfettered clinical development of this novel and transformative therapeutic." Dr. Ramachandran Murali, Kairos VP of Research and Development and inventor of the KROS 401 molecule, commented, "KROS-401, in addition to fibrosis and cancer, opens a new avenue in therapeutic development for neurological disorders such as Alzheimer's disease."

Read More

PHARMACY MARKET

Rx Linc Partners with Scriptera to Enhance Pharmacies Bottomline

Rx Linc | October 08, 2021

Rx Linc, an emerging Business Intelligence pharmacy Switch network, and Scriptera, an organization whose mission is to create data opportunities for their health care partners, announced a strategic partnership that enables pharmacies to monetize their market-level data through a unique revenue sharing program. We are very excited and pleased to bring Scriptera's data platform and industry opportunities to Rx Linc's Switch Network. Rx Linc is focused on delivering data-driven solutions that provide value and opportunity to our pharmacy customers, By partnering with Scriptera, they fit directly into that mission where we now can monetize de-identified pharmacy claims data back to those that are producing the data daily. For too many years, pharmacy has been producing data that provides significant value to the healthcare ecosystem. It's exciting to be able to deliver value in monetizing this data utilization and at a NO cost program. - Josh Cline, Vice President of Rx Linc. Empower your data with a NO-cost program Scriptera is excited to partner with Rx Linc to bring our platform to their network at no cost, The core values of Scriptera and Rx Linc align perfectly as our core mission is to help see pharmacies succeed in such a challenging time. Scriptera unlocks the hidden value that independent pharmacies have been missing out on by empowering their data. - Kevin Laxer, founder of Scriptera. This partnership comes at a critical time in the pharmacy space as Rx Linc strives to deliver more viable revenue streams to pharmacies. Together, Scriptera and Rx Linc are committed to transforming how pharmacies can benefit from providing de-identified healthcare data. About Rx Linc Rx Linc is a Nationwide Switch network delivering data-driven solutions to their pharmacy customers. Since 1998, Rx Linc has been helping a wide range of pharmacies save time and money through data analysis and proactive outreach to minimize claim errors and maximize reimbursements. Rx Linc's data analytics combined with market intelligence improves pharmacy performance by identifying opportunities at every stage of the claims process. About Scriptera Scriptera creates data opportunities for all our partners in order to unlock more precise and faster insights than ever before. We specialize in solutions for pharmacies, wholesalers, manufacturers, and pharmacy companies. Scriptera's team has deep relationships with all these stakeholders to truly understand and identify their unmet needs.

Read More